Citations

Showing 10 of 108083 citations.

Robotic Transanal Minimally Invasive Surgery: Rectourethral Fistula Closure
Gan, Tong, Naik, Nimesh D. , Hebert, Kevin J , Viers, Boyd R. , Kelley, Scott R. , Hebert, Kevin , Behm, Kevin T.

Mayo Clinic

Diseases of the Colon & Rectum | January 17, 2023 | Volume: 66 | Issue: 3 | Pages: e120-e120

10.1097/dcr.0000000000002629 | PMID 40324468 Get It

Differential response to Donepezil in MRI subtypes of mild cognitive impairment
Diaz‐Galvan, Patricia , Lorenzon, Giulia , Mårtensson, Gustav , Cavedo, Enrica , Dubois, Bruno , Westman, Eric , Westman, Eric , Diaz-Galvan, Patricia , Mohanty, Rosaleena , Lista, Simone , Vergallo, Andrea , Kantarci, Kejal , Hampel, Harald , Grothe, Michel J. , Ferreira, Daniel

Mayo Clinic

No container title available | January 17, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2485451/v1 Get It

Abstract Background Donepezil is an approved therapy for the treatment of Alzheimer’s disease (AD). Results across clinical trials have been inconsistent, which may be explained by design-methodological issues, the pathophysiological heterogeneity of AD, and diversity of included study participants. We investigated whether response to Donepezil differs in mild cognitive impaired (MCI) individuals demonstrating different magnetic resonance imaging (MRI) subtypes. Methods From the Hippocampus Study double-blind, randomized clinical trial, we included 173 MCI individuals (donepezil = 83; placebo = 90) with structural MRI data, at baseline and at clinical follow-up assessments (6-12-month). Efficacy outcomes were the annualized percentage change (APC) in hippocampal, ventricular, and total grey matter volumes, as well as in the AD cortical thickness signature. Participants were classified into MRI subtypes as typical-AD, limbic-predominant, hippocampal-sparing, or minimal atrophy at baseline. We compared two subtyping approaches: the conventional categorical approach and an approach based on continuous dimensions. Results Donepezil treated MCI individuals showed slower atrophy rates compared to the placebo group, but only if they belonged to the minimal atrophy or hippocampal sparing subtypes. Importantly, only the continuous subtyping approach, but not the conventional categorical approach, captured this differential response. Conclusions Our data suggest that individuals with MCI, with hippocampal sparing or minimal atrophy subtype, may have improved benefit from donepezil, as compared with MCI individuals with typical or limbic predominant patterns of atrophy. The newly proposed continuous subtyping approach may have advantages compared to the conventional categorical approach. Future research is warranted to demonstrate the potential of subtype stratification for disease prognosis and response to treatment. Trial registration: Clinical Trial.gov Number: NCT00403520, Submission Date: November 21, 2006.
Racial Differences in Germline Genetic Testing for Prostate Cancer: A Systematic Review
Briggs, Logan , Steele, Grant , Qian, Zhiyu , Subbanna, Sara, Alkhatib, Khalid Y. , Labban, Muhieddine , Langbein, Bjoern, Nguyen, David‐Dan , Cellini, Jacqueline , Kilbridge, Kerry L. , Kibel, Adam S. , Rana, Huma Q. , Briggs, Logan G , Steele, Grant L , Trinh, Quoc-Dien , Rana, Huma Q , Cole, Alexander P , Trinh, Quoc‐Dien

Mayo Clinic

JCO Oncology Practice | January 17, 2023 | Volume: 19 | Issue: 5 | Pages: e784-e793

10.1200/op.22.00634 | PMID 36649495 Get It

PURPOSE: Testing for pathogenic variants can aid in oncologic risk stratification and identification of targeted therapies. Despite known disparities in access to prostate cancer (PCa) care, little has been written about access to germline genetic testing (GGT) for Black men and other historically marginalized populations. This systematic review sought to delineate racial/ethnic disparities in GGT for PCa. METHODS: This systematic review identified articles published from January 1996 through May 2021 in PubMed, Web of Science, and Embase. We included studies that reported rates of GGT in men with PCa in the United States by race/ethnicity as reflective of routine clinical care or research. A narrative synthesis was performed. RESULTS: Of 4,309 unique records, 91 studies examining 50 unique study populations met inclusion criteria. Of these, four populations included men who received GGT through routine clinical care, accounting for 4,415 men (72.6% White and 7.2% Black). The other 46 populations included men who received GGT as part of a research study, accounting for 30,824 men (64.3% White and 21.6% Black). Of these 46 research populations, 19 used targeted methods to increase recruitment from a specific demographic. CONCLUSION: Most studies that report GGT rates by race/ethnicity are in research settings. Many of these studies used targeted recruitment methods and subsequently have a greater proportion of Black men than clinical and US population–based studies. Other historically marginalized populations are not well represented. There remains a knowledge gap regarding the extent of racial disparities in the use of GGT, particularly in the clinical setting.
A New Era in Cardiac Rehabilitation Delivery: Research Gaps, Questions, Strategies, and Priorities
Beatty, Alexis L. , Beckie, Theresa M. , Dodson, John A. , Goldstein, Carly M. , Hughes, Joel W. , Kraus, William E. , Olson, Thomas P. , Pack, Quinn R. , Stolp, Haley , Franklin, Barry A. , Martin, Seth S , Stolp, Haley , Wu, Wen-Chih , Beatty, Alexis L , Martin, Seth S. , Thomas, Randal J. , Wu, Wen‐Chih

Mayo Clinic

Circulation | January 17, 2023 | Volume: 147 | Issue: 3 | Pages: 254-266

10.1161/circulationaha.122.061046 | PMID 36649394 Get It

Cardiac rehabilitation (CR) is a guideline-recommended, multidisciplinary program of exercise training, risk factor management, and psychosocial counseling for people with cardiovascular disease (CVD) that is beneficial but underused and with substantial disparities in referral, access, and participation. The emergence of new virtual and remote delivery models has the potential to improve access to and participation in CR and ultimately improve outcomes for people with CVD. Although data suggest that new delivery models for CR have safety and efficacy similar to traditional in-person CR, questions remain regarding which participants are most likely to benefit from these models, how and where such programs should be delivered, and their effect on outcomes in diverse populations. In this review, we describe important gaps in evidence, identify relevant research questions, and propose strategies for addressing them. We highlight 4 research priorities: (1) including diverse populations in all CR research; (2) leveraging implementation methodologies to enhance equitable delivery of CR; (3) clarifying which populations are most likely to benefit from virtual and remote CR; and (4) comparing traditional in-person CR with virtual and remote CR in diverse populations using multicenter studies of important clinical, psychosocial, and cost-effectiveness outcomes that are relevant to patients, caregivers, providers, health systems, and payors. By framing these important questions, we hope to advance toward a goal of delivering high-quality CR to as many people as possible to improve outcomes in those with CVD.
Clinical Utilization of Multimodality Imaging for Myocarditis and Cardiac Sarcoidosis
Chareonthaitawee, Panithaya , Gutberlet, Matthias , Chareonthaitawee, Panithaya

Mayo Clinic

Circulation: Cardiovascular Imaging | January 17, 2023 | Volume: 16 | Issue: 1 | Pages: No page available

10.1161/circimaging.122.014091 | PMID 36649452 Get It

Myocarditis is defined as inflammation of the myocardium according to clinical, histological, biochemical, immunohistochemical, or imaging findings. Inflammation can be categorized histologically by cell type or pattern, and many causes have been implicated, including infectious, most commonly viral, systemic autoimmune diseases, vaccine-associated processes, environmental factors, toxins, and hypersensitivity to drugs. Sarcoid myocarditis is increasingly recognized as an important cause of cardiomyopathy and has important diagnostic, prognostic, and therapeutic implications in patients with systemic sarcoidosis. The clinical presentation of myocarditis may include an asymptomatic, subacute, acute, fulminant, or chronic course and may have focal or diffuse involvement of the myocardium depending on the cause and time point of the disease. For most causes of myocarditis except sarcoidosis, myocardial biopsy is the gold standard but is limited due to risk, cost, availability, and variable sensitivity. Diagnostic criteria have been established for both myocarditis and cardiac sarcoidosis and include clinical and imaging findings particularly the use of cardiac magnetic resonance and positron emission tomography. Beyond diagnosis, imaging findings may also provide prognostic value. This case-based review focuses on the current state of multimodality imaging for the diagnosis and management of myocarditis and cardiac sarcoidosis, highlighting multimodality imaging approaches with practical clinical vignettes, with a discussion of knowledge gaps and future directions.
The Most Memorable Moments From #ASH22
Gangat, Naseema , Szuber, Natasha

Mayo Clinic

The Hematologist | January 17, 2023 | Volume: 20 | Issue: 1 | Pages: No page available

10.1182/hem.v20.1.2023111 Get It

“No Shoes. No Shirt. No Thrombus.” Could Vitamin D Levels Change the Tune for Patients With Antiphospholipid Syndrome?
Brunton, Nichole , Brunton, Nichole E , Casanegra, Ana I. , Houghton, Damon E.

Mayo Clinic

The Hematologist | January 17, 2023 | Volume: 20 | Issue: 1 | Pages: No page available

10.1182/hem.v20.1.2023110 Get It

The epigenetic regulator BRD4 is required for myofibroblast differentiation of knee fibroblasts
Dudakovic, Amel , Bayram, Banu , Bettencourt, Jacob W. , Limberg, Afton K. , Galvan, M. Lizeth, Carrasco, Margarita E., Stans, Britta, Thaler, Roman , Berry, Daniel J., Wijnen, André J. van , Berry, Daniel J. , Sanchez-Sotelo, Joaquin, Abdel, Matthew P , van Wijnen, Andre J , Berry, Daniel J , Morrey, Mark E. , Sánchez‐Sotelo, Joaquín , Berry, Daniel J., Abdel, Matthew P.

Mayo Clinic

Journal of Cellular Biochemistry | January 17, 2023 | Volume: 124 | Issue: 2 | Pages: 320-334

10.1002/jcb.30368 | PMID 36648754 Get It

AbstractArthrofibrosis, which is characterized by excessive scar tissue and limited motion, can complicate the daily functioning of patients after total knee arthroplasty (TKA). Molecular hallmarks of arthrofibrosis include pathologic accumulation of myofibroblasts and disproportionate collagen deposition. Epigenetic mechanisms, including posttranslation modification of histones, control gene expression and may regulate fibrotic events. This study assessed the role of the bromodomain and extra‐terminal (BET) proteins on myofibroblast differentiation. This group of epigenetic regulators recognize acetylated lysines and are targeted by a class of drugs known as BET inhibitors. RNA‐seq analysis revealed robust mRNA expression of three BET members (BRD2, BRD3, and BRD4) while the fourth member (BRDT) is not expressed in primary TKA knee outgrowth fibroblasts. RT‐qPCR and western blot analyses revealed that BET inhibition with the small molecule JQ1 impairs TGFβ1‐induced expression of ACTA2, a key myofibroblast marker, in primary outgrowth knee fibroblasts. Similarly, JQ1 administration also reduced COL3A1 mRNA levels and collagen deposition as monitored by picrosirius red staining. Interestingly, the inhibitory effects of JQ1 on ACTA2 mRNA and protein expression, as well as COL3A1 expression and collagen deposition, were paralleled by siRNA‐mediated depletion of BRD4. Together, these data reveal that BRD4‐mediated epigenetic events support TGFβ1‐mediated myofibroblast differentiation and collagen deposition as seen in arthrofibrosis. To our knowledge, these are the first studies that assess epigenetic regulators and their downstream events in the context of arthrofibrosis. Future studies may reveal clinical utility for drugs that target epigenetic pathways, specifically BET proteins, in the prevention and treatment of arthrofibrosis.
Differentiation of acute graft-versus-host disease from drug reaction in skin by a novel tissue-based biomarker assay
Dasari, Surendra , Damodaran, Sindhuja Sominidi, Hashmi, Shahrukh K. , Gibson, Lawrence E. , Patnaik, Mrinal M. , Litzow, Mark R. , Meves, Alexander , Lehman, Julia S. , Li, Ming , el‐Azhary, Rokea A. , Lazarus, Hillard M. , Hogan, William J. , Kenderian, Saad S.

Mayo Clinic

No container title available | January 17, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2481845/v1 Get It

Abstract Acute graft-versus-host disease (GVHD), a serious complication of allogeneic hematopoietic cell transplantation (HCT), frequently involves the skin. Since clinicopathologic features of GVHD can mimic those of certain drug eruptions, accurate diagnosis can be challenging. We aimed to develop a tissue-based molecular assay to improve differentiation of GVHD from vacuolar interface drug eruption in the post-HCT period. After identifying 62 putative tissue-based biomarkers using unbiased molecular methods, we incorporated 26 into a quantitative RT-PCR assay. We tested skin biopsy specimens showing vacuolar interface changes attributable to either acute GVHD (n=67) or drug reaction (n=17), as classified by meticulous review of clinical features and course. Data were incorporated into clinical-molecular fusion diagnostic models. Significant differences in the expression of several genes, including MX1, MNDA, OAS, LIMA1, GSTM5, and SPP1, were detected between the two diagnostic groups (p<0.05). The optimal fusion model, which incorporated quantitative expression of MX1, MNDA, OAS, and GSTM5, as well as the clinical feature of diarrhea, imparted high diagnostic accuracy (receiver operating characteristic area-under-curve: 0.89). This novel tissue-based diagnostic molecular assay and fusion model demonstrates potential to improve distinction of GVHD from drug eruptions in the post-HCT setting. Multicenter validation studies are required.
Does metabolite matter? Defining target itraconazole and hydroxy‐itraconazole serum concentrations for blastomycosis
Firkus, Danielle , Saleh, Omar Abu , Enzler, Mark J., Jannetto, Paul J. , Mara, Kristin C. , Vergidis, Paschalis , Rivera, Christina G. , Stevens, Ryan W. , Abu Saleh, Omar M, Mara, Kristin C , Vergidis, Paschalis , Rivera, Christina G , Stevens, Ryan W

Mayo Clinic

Mycoses | January 17, 2023 | Volume: 66 | Issue: 5 | Pages: 412-419

10.1111/myc.13565 | PMID 36648362 Get It

AbstractBackgroundItraconazole is the recommended first‐line treatment for mild‐to‐moderate blastomycosis and consolidation treatment of moderate‐to‐severe disease. Itraconazole is metabolised into three metabolites, including an active metabolite hydroxy‐itraconazole. Literature provides little evidence indicating whether therapeutic drug monitoring targets should be based on itraconazole parent compound alone or a sum of itraconazole and hydroxy‐itraconazole serum concentrations.ObjectivesThis study aims to compare clinical outcomes and adverse drug events (ADEs) of combined itraconazole and hydroxy‐itraconazole concentrations versus itraconazole parent compound alone in patients with blastomycosis.Patients/MethodsThis study was a retrospective cohort review of patients ≥18 years with probable or proven Blastomyces infection who received itraconazole with at least one documented serum itraconazole concentration. The primary outcome was rate of partial or complete treatment response across three patient groups: (1) Itraconazole parent compound >1.0 mcg/ml (parent), (2) parent compound <1.0 mcg/ml, but a combined itraconazole and hydroxy‐itraconazole >1.0 mcg/ml (combined) and (3) failure to achieve a combined or parent concentration >1.0 mcg/ml (subtherapeutic) for >75% of the duration of itraconazole therapy.ResultsA total of 80 patients were included (parent = 32, combined = 36, subtherapeutic = 12). No statistically significant difference was observed for rate of partial or complete treatment response (97% parent vs 94% combined, p = .99). Significantly higher mortality due to blastomycosis was observed in patients in the subtherapeutic group (0% parent vs 3% combined vs 25% subtherapeutic, p = .01).ConclusionsThis study supports an itraconazole therapeutic target combining itraconazole and hydroxy‐itraconazole >1.0 mcg/ml for blastomycosis treatment.